In our new publication, we speak to key opinion leaders and industry experts to uncover novel strategies for commercializing immunodermatology therapies in a crowded market landscape.
Today, there are more than 80 treatments in development for atopic dermatitis and psoriasis. The landscape is booming with treatment innovations. However, the rise in research and development has created a crowded market that healthcare professionals struggle to navigate. Dermatologists face an abundance of data and more complex barriers to access than ever before. These challenges often prevent them from prescribing novel treatments to patients.
In this report, we speak to key opinion leaders and biopharmaceutical executives to reveal insights on the market landscape and explore novel opportunities for life science companies to become valued partners for stakeholders they serve.